In AI answers, Pfizer is a name on many lists but rarely the reason for one

This snapshot, measured 2026-09-29, covers 1,250 answers from ChatGPT, Claude, Gemini, Perplexity and Grok to category questions that never named a brand. Pfizer was named in 174 of them. That is level with CVS Health and just behind Johnson & Johnson and UnitedHealth Group among the sector peers. Grok named Pfizer far more often (55 of 250) than the other four assistants, which each named it in 28 to 32 of 250.

In the 21 stored answers supplied, Pfizer mostly appears as a roll-call entry. It sits in lists of oncology pipeline leaders, patient assistance programs, congressional witnesses on drug pricing, and executive-pay disclosures. Most of the credit tags recorded for Pfizer were 'Not Substantive'. Only a handful were tied to Safety & Compliance, Reliability & Operations, Financial Performance or Sustainability & Ethics.

The answers do sometimes give Pfizer a specific role. Gemini's oncology answer described a pipeline reshaped by the Seagen acquisition. Claude's vaccine-supply answer singled Pfizer out for a delivery-rate figure and cold-chain work with UPS and FedEx. Perplexity credited Pfizer with an ESG modifier in its annual bonus program. Other answers used Pfizer as a legal and reputational reference point. Gemini cited a 2009 settlement over off-label promotion and alleged kickbacks. Claude listed an inclacumab trial among recent phase 3 disappointments. ChatGPT placed Pfizer 50th in an Axios Harris Poll ranking.

Visibility varied by question intent. Pfizer's highest rates were for leadership questions and for 'avoid' style questions. It was absent from questions about value and service.

PeakMetrics' news index logged 19,027 Pfizer mentions in the last 30 days, 3,546 of them with Pfizer in the headline. That volume is close to Merck, Amgen and Eli Lilly and well above UnitedHealth Group, CVS Health and Cigna.

The recent headlines point in four directions. Two are vaccine conspiracy items on brighteon.com, about cell towers and 5G graphene in the COVID vaccine. One reports that Karnataka halted business with Pfizer and cancelled licences of 16 firms over a counterfeit medicine racket. One says CEO Bourla plans to attend a White House state dinner for China's Xi. One covers a $12M upfront payment from Medicus to Pfizer in an antibody-drug conjugate (ADC) deal with over $1B in milestones.

Among the supplied answers, the assistants talk about pipeline strategy, program eligibility, historical settlements and supply chains. The press mix includes fringe vaccine claims, a state government's action on counterfeit medicines, CEO diplomacy and licensing deals. None of the supplied answers touched the Karnataka episode or the conspiracy content. Those items are a small sample of headlines, so this is a contrast in emphasis, not a full accounting of either side.

Heavy coverage has not turned into substantive credit in these answers. Pfizer's press volume is among the highest in its peer set, yet the answers mostly used it as a name in a list. The cited history the assistants reached for, such as the 2009 settlement, is older than anything in the current headline set.

A comms team would start with the questions where Pfizer is absent or thin. Value and service showed no visibility at all in this snapshot. Where Pfizer does appear, ask what the answer credits it for. Pipeline, cold-chain delivery and ESG-linked pay each showed up as a specific, quotable hook. Settlement history and trial-failure references showed up when the question invited them.

Because Grok named Pfizer far more often than the other assistants, its answers are worth reading separately from the rest. These are single snapshots of live answers, and they will vary between runs. Treat them as a baseline for repeat measurement, not a ranking.